Mechanism-Driven Evolution of Fertility-Sparing Treatment and Precision Management of Special Populations in Endometrial Cancer: A Review
Open Access
Abstract
Endometrial cancer is increasingly diagnosed in patients who have not yet completed childbearing. For carefully selected patients with grade 1 endometrioid endometrial carcinoma confined to the endometrium, fertility-sparing treatment (FST) can preserve reproductive potential but requires rigorous histologic surveillance. In eligible patients, oral progestins and/or the levonorgestrel-releasing intrauterine system (LNG-IUS) remain the mainstay of fertility-sparing treatment, with hysteroscopic lesion resection incorporated in selected cases. Obesity, polycystic ovary syndrome, abnormalities in glucose metabolism, molecular subtype, and primary or acquired progestin resistance collectively contribute to heterogeneity in treatment response and the risk of recurrence. This narrative review critically integrates current guidelines, randomized controlled trials, prospective studies, retrospective cohorts, and early exploratory evidence to evaluate the biological rationale, clinical positioning, efficacy, safety, and maturity of evidence for progestin-based therapy, metabolic interventions, combined endocrine approaches, molecularly guided strategies, and exploratory immunotherapeutic approaches. We further propose an integrated clinical pathway encompassing candidate selection, molecular assessment, response evaluation, transition to pregnancy, retreatment after recurrence, and timely conversion to definitive surgery. Importantly, this review distinguishes guideline-supported approaches from adjunctive, investigational, and exploratory strategies. Major evidence gaps include inconsistent definitions of treatment response, limited prospective molecularly stratified data, uncertain reproductive safety of emerging systemic therapies, and insufficient long-term data on pregnancy outcomes and offspring.Keywords
Funding Information
- Capital’s Funds for Health Improvement and Research (2026-2-2112)
- Capital’s Funds for Health Improvement and Research (2024-1-2112)
- Beijing Physician Scientist Training Project (BJPSTP-2025-49)
This publication has 40 references indexed in Scilit:
- Using Machine Learning to Predict the Prognosis in Endometrial Cancer Patients Undergoing Fertility‐Sparing TreatmentCancer Medicine, 2025
- Fertility-sparing treatment for overweight patients with early-stage endometrial cancer or atypical endometrial hyperplasia under weight loss interventionJournal of Cancer Research and Clinical Oncology, 2025
- GLP-1 Receptor Agonists and Cancer Risk in Adults With ObesityJAMA Oncology, 2025
- Fertility-sparing treatment for atypical endometrial hyperplasia and endometrial cancerCochrane Database of Systematic Reviews, 2025
- Fertility-preserving treatment for stage IA endometrial cancer: a systematic review and meta-analysisAmerican Journal of Obstetrics and Gynecology, 2024
- Glucagon-Like Peptide 1 Receptor Agonists and 13 Obesity-Associated Cancers in Patients With Type 2 DiabetesJAMA Network Open, 2024
- Prospective phase II trial of levonorgestrel intrauterine device: nonsurgical approach for complex atypical hyperplasia and early-stage endometrial cancerAmerican Journal of Obstetrics and Gynecology, 2020
- Microsatellite instability in endometrial cancer: New purpose for an old testCancer, 2019
- Association of Polymerase e–Mutated and Microsatellite-Instable Endometrial Cancers With Neoantigen Load, Number of Tumor-Infiltrating Lymphocytes, and Expression of PD-1 and PD-L1JAMA Oncology, 2015
- Regression, relapse, and live birth rates with fertility-sparing therapy for endometrial cancer and atypical complex endometrial hyperplasia: a systematic review and metaanalysisAmerican Journal of Obstetrics and Gynecology, 2012